HOME >> BIOLOGY >> NEWS
Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkin's Lymphoma announced by IDEC Pharmaceuticals

Final results of the two ZEVALIN pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals at 42nd annual Society of Hematology meeting -- Three Additional Studies of ZEVALIN Also Presented

SAN FRANCISCO, CALIFORNIA -- Dec. 5, 2000 -- IDEC Pharmaceuticals Corporation (Nasdaq:IDPH) announced the final results of two pivotal trials of ZEVALIN (Ibritumomab Tiuxetan), an investigational radioimmunotherapy, during oral presentations at the 42nd Annual Meeting of the American Society of Hematology (ASH).

Thomas E. Witzig, M.D. of the Mayo Clinic, Rochester, MN, today delivered an oral presentation of a Phase III randomized, controlled study of 143 patients with relapsed or refractory low grade, follicular, or CD20-positive transformed B-cell Non-Hodgkins Lymphoma (NHL). He noted that the ZEVALIN combined with Rituxan arm of the study showed an overall response rate (ORR) of 80 percent, compared to the Rituxan (Rituxumab) alone control arm, which showed an overall response rate of 56 percent. A treatment course for ZEVALIN includes a Rituxan infusion (250 mg/m.2) on day one, followed by infusions of Rituxan (250 mg/m2) and ZEVALIN (at a standard radiation dose of 0.4 mCi/kg of patient body weight) on day eight. A treatment course of the Rituxan control consisted of four weekly doses of 375 mg/m2 of Rituxan.

Dr. Witzig said that 30 percent of the ZEVALIN patients achieved complete responses to therapy. Sixteen percent of Rituxan patients achieved complete responses. To date duration of response estimates between ZEVALIN plus Rituxan and Rituxan alone are not statistically different but further analysis will be conducted as data matures.

ZEVALIN associated toxicity was primarily hematologic, transient and reversible. Thirty-two percent of patients in the ZEVALIN arm of the study experienced Grade 4 neutropenia (neutrophil count below 500/mm3) and five percent experienced Grade 4 thrombocytope
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
4-Dec-2000


Page: 1 2 3 4

Related biology news :

1. Final Alert: 16th EORTC NCI AACR Symposium
2. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
3. Final of the 2003/04 Research Councils Business Plan Competition
4. L.A.Times Book Prize Finalist: Book On Evolution Of Bird Flight
5. Could A Nasal Vaccine Finally Get Rid Of The Black Death?
6. Last Comment Sought On Agents Proposed For Report On Carcinogens; A Final ForData On Saccharin, And A Re-Review Of Dioxin Announced
7. Warren Pharmaceuticals publishes results of preclinical evaluation
8. U of T microbiologists achieve results with pattern recognition software
9. Loss of circadian genes results in epilepsy
10. VIB presents its annual results at BIO2004 in San Francisco
11. Scientists discover why not enough choline results in fewer brain cells, poorer memory

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates ... of how to continue to feed a growing nation. At the same time, many ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
Breaking Biology Technology:
Cached News: